Pretomanid is becoming tested as Element of a mix routine which includes moxifloxacin and PZA to the treatment of both of those drug-prone and drug-resistant tuberculosis (ClinicalTrials.gov identifier: NCT02193776). Bedaquiline, approved via the US FDA for treatment of multidrug-resistant tuberculosis in 2012, is additionally currently being inves